{"id":989,"date":"2021-09-24T15:40:59","date_gmt":"2021-09-24T14:40:59","guid":{"rendered":"https:\/\/www.sedapds.com\/?p=989"},"modified":"2021-09-24T16:01:27","modified_gmt":"2021-09-24T15:01:27","slug":"life-science-integrates-presentation-with-paul-stott","status":"publish","type":"post","link":"https:\/\/www.sedapds.com\/news\/life-science-integrates-presentation-with-paul-stott\/","title":{"rendered":"Life Science Integrates Presentation with Paul Stott"},"content":{"rendered":"

Joined by a panel of leading scientists, Seda\u2019s CEO Paul Stott took part in\u00a0<\/span>Bio Integrates’ 2021 recorded sessions hosted by Life Science Integrates – Track 2 – \u2018It\u2019s about time\u2019. The session covers ways of accelerating product development, the approach to development and approval of drug products, therapeutics & novel clinical trials, and the continuum of product development. Following the rapid development of COVID-19 vaccines due to the pandemic, the public have been shown just how fast medicines can be developed, assessed and approved, which has led to discussions on how these timelines can be accelerated outside of a pandemic. <\/span>\u00a0<\/span><\/p>\n

During the session the making of the COVID-19 vaccine was discussed by a research group leader from Oxford University and further details were given surrounding trials around safety and efficacy as well as the manufacturing process. The challenges of clinical trials on COVID-19 due to waves in different countries and different phases of the pandemic were also discussed, along with certain risks and decisions which had to be made in this time. <\/span>\u00a0<\/span><\/p>\n

\"SedaPaul Stott commented \u2018it was a great opportunity to hear directly from those involved first hand in the extraordinary efforts to develop novel COVID vaccines and to discuss how these learnings could be applied more broadly.\u2019<\/span><\/i>\u00a0<\/span><\/p>\n

 <\/p>\n

Another\u00a0discussion point was\u00a0regulatory authorities\u00a0and the impact\u00a0they have on the\u00a0drug development process including\u00a0\u2013 initial discussions, engagement, balanced approach,\u00a0staffing\u00a0and\u00a0skill set shortages.\u00a0Looking into the future it will be\u00a0a big question as to how\u00a0we can\u00a0work together to\u00a0shorten regulatory steps.<\/span>\u00a0<\/span><\/p>\n

Other areas covered in the session include big pharma vs SMEs, access to facilities and materials, supply chain issues, balancing supply and demand with staff skill sets and resources. With the main focus being on the shortening of timescales, efficiency and cost savings following the pandemic within the life sciences industry.<\/span>\u00a0<\/span><\/p>\n

The presentation is free to watch on\u00a0the\u00a0<\/span>Life Science Integrates<\/span><\/a>\u00a0website.\u00a0You can also watch recorded sessions\u00a0exploring\u00a0raising investments and meeting milestones,\u00a0life-science companies moving location due to funding gaps and Brexit\u00a0along\u00a0with\u00a0ongoing changes\u00a0into 2021 and beyond.<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Joined by a panel of leading scientists, Seda\u2019s CEO Paul Stott took part in\u00a0Bio Integrates’ 2021 recorded sessions hosted by Life Science Integrates – Track 2 – \u2018It\u2019s about time\u2019. The session covers ways of accelerating product development, the approach to development and approval of drug products, therapeutics & novel clinical trials, and the continuum…<\/p>\n","protected":false},"author":2,"featured_media":999,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[1],"tags":[],"yoast_head":"\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\n\n\n\n\t\n